SCHEMBL1424

SCHEMBL1424

CN(C)/C=C/C(=O)c1ccccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.61
MAPT P10636 6/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
KDM4E B2RXH2 2/20 0.58
LMNA P02545 2/20 0.58
PKM P14618 2/20 0.58
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HTT P42858 3/20 0.53
KMT2A Q03164 3/20 0.52
GAA P10253 2/20 0.52
MEN1 O00255 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
GPR52 Q9Y2T5 1/20 0.51
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
KRAS P01116 1/20 0.49
MITF O75030 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1425 1.00 RECQL (0.61) RECQLMAPTNPC1RAB9AKDM4E
SCHEMBL31276286 1.00 RECQL (0.61) RECQLMAPTNPC1RAB9AKDM4E
SCHEMBL15709976 1.00 RECQL (0.61) RECQLMAPTNPC1RAB9AKDM4E
SCHEMBL14354329 0.81 GPR52 (0.57) RECQLMAPTNPC1RAB9AKDM4E
SCHEMBL14354330 0.81 GPR52 (0.57) RECQLMAPTNPC1RAB9AKDM4E
SCHEMBL23251391 0.80 RECQL (0.61) RECQLMAPTNPC1RAB9ALMNA
SCHEMBL10950293 0.80 MAPT (0.64) MAPTNPC1RAB9AKDM4ELMNA
SCHEMBL10950289 0.80 MAPT (0.64) MAPTNPC1RAB9AKDM4ELMNA
SCHEMBL30208792 0.80 MAPT (0.64) MAPTNPC1RAB9AKDM4ELMNA
SCHEMBL30046046 0.80 RECQL (0.61) RECQLMAPTNPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180273906-A1 MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS IPS HEART 2018-09-27 US claimed
US-20060074108-A1 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition BIODERM RESEARCH (US) 2006-04-06 US claimed
US-20260042765-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORP (US) 2026-02-12 US disclosed
US-12415809-B2 Pyrrolotriazine compounds as tam inhibitors INCYTE CORPORATION (US) 2025-09-16 US disclosed
CN-116253731-B Preparation method of indolizine compound 宜春学院 2025-01-28 CN disclosed
US-20240124463-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2024-04-18 US disclosed
EP-4321513-A2 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS Incyte Corporation (US) 2024-02-14 EP disclosed
EP-3436461-B1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORP (US) 2023-11-01 EP disclosed
EP-3601216-B1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION ARBUTUS BIOPHARMA CORP (CA) 2023-10-25 EP disclosed
EP-3601216-B1 SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION ARBUTUS BIOPHARMA CORP (CA) 2023-10-25 EP disclosed
CN-116253731-A Preparation method of indolizine compound 宜春学院 2023-06-13 CN disclosed
EP-0453731-A2 Improved process for the synthesis of N-3-(1H-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1991-10-30 EP disclosed
US-4876252-A ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN AMERICAN CYANAMID COMPANY (US) 1989-10-24 US disclosed
US-4788195-A TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS AMERICAN CYANAMID COMPANY (US) 1988-11-29 US disclosed
EP-0233461-A2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1987-08-26 EP disclosed
EP-0029103-B1 6- AND 8-HETEROARYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES AMERICAN CYANAMID COMPANY (US) 1983-05-18 EP disclosed
US-4281000-A Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents AMERICAN CYANAMID COMPANY (US) 1981-07-28 US disclosed
EP-0029103-A1 6- and 8-Heteroaryl-1,2,4-triazolo(4,3-b)pyridazines AMERICAN CYANAMID COMPANY (US) 1981-05-27 EP disclosed
US-4260756-A TRANQUILIZERS AMERICAN CYANAMID COMPANY (US) 1981-04-07 US disclosed
EP-0025819-A1 Substituted pyrazolo (1,5-a) pyrimidines, and their preparation AMERICAN CYANAMID COMPANY (US) 1981-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180273906-A1 MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS EXOSC9, EXOSC5, EXOSC4 RECQL 1922/4885MAPT 2473/4885NPC1 1167/4885
US-20260042765-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MAP2K2, TTK, MAP2K5 RECQL 4522/4885MAPT 3577/4885NPC1 4002/4885
US-12415809-B2 Pyrrolotriazine compounds as tam inhibitors MERTK, MAP3K15, MAP3K5 RECQL 4368/4885MAPT 3032/4885NPC1 3819/4885
US-20240124463-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MERTK, MAP3K15, MAP3K5 RECQL 4368/4885MAPT 3032/4885NPC1 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.